TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by Goldman Sachs Group Inc.

Goldman Sachs Group Inc. decreased its position in TG Therapeutics, Inc. (NASDAQ:TGTX) by 2.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,649,837 shares of the biopharmaceutical company’s stock after selling 41,113 shares during the quarter. Goldman Sachs Group Inc. owned 1.09% of TG Therapeutics worth $28,179,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in TGTX. New York State Common Retirement Fund raised its holdings in TG Therapeutics by 1.2% during the fourth quarter. New York State Common Retirement Fund now owns 56,208 shares of the biopharmaceutical company’s stock worth $960,000 after purchasing an additional 663 shares in the last quarter. Kestra Advisory Services LLC raised its holdings in TG Therapeutics by 8.2% during the third quarter. Kestra Advisory Services LLC now owns 16,342 shares of the biopharmaceutical company’s stock worth $137,000 after purchasing an additional 1,240 shares in the last quarter. Valeo Financial Advisors LLC raised its holdings in TG Therapeutics by 2.4% during the fourth quarter. Valeo Financial Advisors LLC now owns 63,300 shares of the biopharmaceutical company’s stock worth $1,081,000 after purchasing an additional 1,500 shares in the last quarter. Pingora Partners LLC acquired a new stake in TG Therapeutics during the fourth quarter worth approximately $27,000. Finally, PNC Financial Services Group Inc. raised its holdings in TG Therapeutics by 131.7% during the third quarter. PNC Financial Services Group Inc. now owns 3,543 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 2,014 shares in the last quarter. Institutional investors and hedge funds own 58.58% of the company’s stock.

TG Therapeutics Stock Performance

NASDAQ:TGTX opened at $17.65 on Monday. The firm’s fifty day moving average price is $16.03 and its 200 day moving average price is $15.99. TG Therapeutics, Inc. has a 1-year low of $6.46 and a 1-year high of $26.95. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.62 and a quick ratio of 2.84. The firm has a market cap of $2.73 billion, a price-to-earnings ratio of 76.74 and a beta of 2.30.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). TG Therapeutics had a net margin of 14.24% and a return on equity of 31.34%. The firm had revenue of $63.47 million during the quarter, compared to analysts’ expectations of $54.60 million. During the same quarter last year, the business earned ($0.28) earnings per share. The business’s quarterly revenue was up 713.5% on a year-over-year basis. On average, sell-side analysts expect that TG Therapeutics, Inc. will post -0.01 EPS for the current year.

Analysts Set New Price Targets

TGTX has been the topic of a number of research analyst reports. HC Wainwright raised their price objective on shares of TG Therapeutics from $45.00 to $49.00 and gave the stock a “buy” rating in a report on Thursday, May 2nd. JPMorgan Chase & Co. restated an “overweight” rating and set a $25.00 target price on shares of TG Therapeutics in a research report on Thursday, April 18th. The Goldman Sachs Group raised their target price on shares of TG Therapeutics from $12.00 to $13.00 and gave the stock a “neutral” rating in a research report on Thursday, February 29th. Finally, LADENBURG THALM/SH SH raised their target price on shares of TG Therapeutics from $39.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, May 2nd. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $29.83.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.